How to Get Wegovy Prescribed Online in Canada (2026)

Where a weight-related Ozempic request runs into the fact that Ozempic isn't authorized for that purpose, Wegovy's indication expressly includes "chronic weight management" — with eligibility criteria written into the monograph in numbers you can read before you ever speak to a practitioner.

So the friction moves. It stops being "will a prescriber consider this at all?" and becomes two questions:

1. Do I meet the criteria as written? They are specific: BMI thresholds, and at the lower one, a weight-related comorbidity.
2. Who pays? The harder question, and where Wegovy diverges most sharply from Ozempic — drug plans treat weight-management and diabetes medications very differently.

This guide follows that order: criteria, routes, then coverage.

The criteria below are quoted from the Health Canada authorized product monograph. Meeting them on paper is not the same as being prescribed — a practitioner assesses your full history — but they tell you what the conversation is anchored to.

"WEGOVY® (semaglutide injection) is indicated: as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in: Adult patients with an initial body mass index (BMI) of 30 kg/m2 or greater (obesity), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbidity such as hypertension, type 2 diabetes mellitus, dyslipidemia, or obstructive sleep apnea."

The same section sets out adolescent criteria:

"Pediatric patients aged 12 to less than 18 years: with an initial BMI at the 95th percentile or greater for age and sex (obesity; see Table 1), and a body weight above 60 kg (132 lbs), and an inadequate response to reduced calorie diet and physical activity alone."

And two further authorized indications:

"to reduce the risk of non-fatal myocardial infarction in adults with established cardiovascular disease and BMI equal to or greater than 27 kg/m2"

"for the treatment of non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis)."

The monograph flags that the MASH indication "is authorized under the NOC/c Policy based on histopathological improvements. Continued approval for this indication may be contingent upon the verification and description of clinical benefit in a confirmatory trial." That is Health Canada's Notice of Compliance with conditions pathway.

Two Limitations of Use from the monograph are worth knowing before an intake:

"WEGOVY® should not be used in combination with any other semaglutide-containing drug (e.g. Ozempic®, Rybelsus®) or any other GLP-1 receptor agonist."

"WEGOVY® is not indicated for the treatment of Type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis."

If you are currently taking another semaglutide-containing product or another GLP-1, say so on your intake.

Your family doctor. Well placed to document what the criteria require — measured height and weight rather than self-reported, plus any comorbidity already in your chart. That documentation matters later, at the coverage stage. Slowest to start.

A walk-in clinic. Faster to reach a clinician, weaker on records. A walk-in can measure you, but won't have your history of prior treatments — exactly what a private insurer tends to ask about when reviewing a claim.

Telehealth. Structured intake suits an indication with numeric criteria, and it's a practical route if you have no regular provider. Check three things: whether measurements are self-reported or verified, who manages the dose-escalation schedule and follow-up, and whether fees recur. Services differ considerably.

One common surprise: Felix, a telehealth platform we earn a commission from, does not dispense Wegovy or SEVMIA, the newer generic version Health Canada also approved. Its online intake is a weight-management application, and what it dispenses if a practitioner prescribes is apo-semaglutide — approved by Health Canada for type 2 diabetes (Apo-Semaglutide Injection Product Monograph, Section 1 Indications, date of authorization 2026-05-01), so prescribing it for weight management is off-label, at the prescriber's clinical judgment. The initial assessment fee is $0.00; apo-semaglutide is $149.00/month at the 0.25, 0.5 and 1.0 mg pen strengths and more at higher maintenance strengths. Approval is not guaranteed, and Felix operates in some provinces but not all — check that yours is one.

If Wegovy specifically is what you want, confirm a provider dispenses it before paying anything. Compare all telehealth providers on our hub rather than relying on any one provider's own description.

A pharmacist. Scope is uneven across the country. The Canadian Pharmacists Association's national chart shows Alberta as the only jurisdiction where independent pharmacist prescribing for any Schedule I drug is implemented; all other provinces and territories are marked not implemented. Renewing or extending an existing prescription is implemented everywhere except Nunavut, and adapting a dose, formulation, or regimen everywhere except the Northwest Territories and Nunavut (CPhA).

Outside Alberta, then, expect a pharmacist to maintain or adapt an existing Wegovy prescription rather than start one. Within Alberta the authority on the books isn't a blanket one either: it belongs to pharmacists who hold Additional Prescribing Authorization (APA), a credential layered on top of a standard pharmacy licence, not automatic for every pharmacist in the province. Whether an APA-holding pharmacist exercises it for a given medication is still their own clinical judgment and practice setting, as with every prescriber. Worth asking locally rather than inferring from a scope chart.

1. Intake. Expect height, weight, and BMI to be captured explicitly, alongside medical history, current medications, allergies, and any weight-related conditions such as hypertension, type 2 diabetes, dyslipidemia, or sleep apnea. Report accurately — an inaccurate intake produces an assessment that isn't about you.
2. Practitioner review. Asynchronous means a licensed practitioner reviews your written submission on their own schedule with no live conversation; synchronous means a scheduled video or phone consult. Given a dose-escalation schedule, it's reasonable to want a live conversation — check which model applies before paying.
3. The decision. A practitioner may approve, decline, ask for measurements or records, or suggest another approach. Meeting the BMI threshold is one input among several and does not entitle you to a prescription, and paying an assessment fee never guarantees an outcome.
4. Prescription and fill. If issued, it goes to the pharmacy you nominate, or to a partner or mail-order pharmacy.
5. Follow-up and coverage paperwork. Two things run in parallel: the dose-escalation schedule, and — if you're claiming against a private plan — any prior authorization forms your insurer requires. Find out who completes them; it's a common stall point.

We don't publish "prescription in X hours" figures. Those are provider marketing claims and we have not verified them.

A valid prescription can generally be filled at any licensed Canadian pharmacy — chain, independent, or mail-order. Cash prices are set by each pharmacy and vary.

Across 11 verified Canadian pharmacies, Wegovy runs $113–$550 per pen as of July 18, 2026.

Live pharmacy-by-pharmacy listings are on the Wegovy drug page. A generic equivalent is now in the picture: Health Canada authorized SEVMIA (Apotex) on June 29, 2026, announced the following day as the first approval for a generic equivalent of Wegovy (Apotex/PR Newswire, June 30, 2026). Pricing is tracked in our Sevmia cost guide, with provincial detail for Ontario and Alberta; our methodology page documents how we verify prices.

Coverage is the defining issue for Wegovy, and it is not the same as for Ozempic. The CMA notes that GLP-1 drugs like Ozempic are usually covered for type 2 diabetes, but that "coverage looks very different for weight management; only a small number of private insurance plans offer partial coverage for GLP-1 drugs approved for chronic weight management, and public drug plans generally do not cover them" (CMA).

The route that is on-label is also, for most people, the one least likely to be publicly funded; the CMA observes that when insurance doesn't cover it, many Canadians pay out of pocket. So check your private plan's wording for weight-management drugs before you start, and expect prior authorization rather than automatic approval where coverage exists. The CMA further notes that wider generic availability is expected to increase the number of plans covering GLP-1 drugs for weight loss — a change to watch, not to count on today.

Not having a regular provider is common and is not a barrier to being assessed. An estimated 5.9 million adults in Canada do not have a family doctor, nurse practitioner, or primary care team they see regularly, according to the OurCare survey led by Dr. Tara Kiran at Unity Health Toronto in partnership with the Canadian Medical Association (CMA, December 8, 2025).

For Wegovy specifically, the gap creates a documentation problem more than an access problem. The criteria reference an initial BMI and, at the lower threshold, a weight-related comorbidity — usually established through prior measurements and labs kept in a chart that, without a regular provider, may not exist in one place. Gather what you can before an intake: recent bloodwork, blood pressure readings, prior diagnoses, and your pharmacy's medication history. It makes the assessment more accurate and any insurance paperwork easier.

Our guide to getting a GLP-1 prescription without a family doctor covers all of this in more depth: walk-in clinics, telehealth, what pharmacists can and can't do in your province, and what to settle before your first prescription runs out.

Any website offering Wegovy without a prescription is a red flag. The CMA states it directly: if a website says you can get a GLP-1 drug without a prescription, that's a major red flag (CMA).

Health Canada lists signs that an online pharmacy may be fraudulent, including that it "Does not require a valid prescription," offers drugs at very low discounted prices, does not provide a "bricks and mortar" business address, or is located outside of Canada. A legitimate online pharmacy "Requires a valid prescription from a physician or other health practitioner licensed to practice in Canada," is licensed by a provincial or territorial pharmacy regulatory authority, has a Canadian-licensed pharmacist available to answer questions, and provides a street address located in Canada (Health Canada, Choosing a safe online pharmacy).

Health Canada warns that buying from a fraudulent online pharmacy means "You may end up with a drug that contains wrong or harmful ingredients, or no medicinal ingredients at all," and notes that medications requiring refrigeration "may not be stored or transported properly" by such sellers — relevant for any injectable. On importation: "You cannot legally import a prescription drug unless you are a practitioner, a drug manufacturer, a wholesale druggist, a registered pharmacist, or a resident of a foreign country while a visitor in Canada."

Because coverage for weight-management drugs is limited, cost pressure is real — and that pressure is exactly what unauthorized sellers target. A price far below what licensed Canadian pharmacies charge is a warning sign, not a bargain.